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Anticipation is the phenomenon whereby age of onset in genetic disease decreases in successive generations. Three independent reports
have claimed anticipation in Creutzfeldt-Jakob disease (CJD) caused by the c.598G>A mutation in PRNP encoding a p.Glu200Lys
(E200K) substitution in the prion protein. If confirmed, this finding would carry clear implications for genetic counseling. We analyzed
pedigrees with this mutation from four prion centers worldwide (n ¼ 217 individuals with the mutation) to analyze age of onset and
death in affected and censored individuals. We show through simulation that selective ascertainment of individuals whose onset falls
within the historical window since the mutation’s 1989 discovery is sufficient to create robust false signals both of anticipation and of
heritability of age of onset. In our data set, the number of years of anticipation observed depends upon how strictly the data are limited
by the ascertainment window. Among individuals whose disease was directly observed at a study center, a 28-year difference between
parent and child age of onset is observed (p ¼ 0.002), but including individuals ascertained retrospectively through family history
reduces this figure to 7 years (p ¼ 0.005). Applying survival analysis to the most thoroughly ascertained subset of data eliminates the
signal of anticipation. Moreover, even non-CJD deaths exhibit 16 years anticipation (p ¼ 0.002), indicating that ascertainment
bias can entirely explain observed anticipation. We suggest that reports of anticipation in genetic prion disease are driven entirely by
ascertainment bias. Guidelines for future studies claiming statistical evidence for anticipation are suggested.Introduction
Prion diseases are uniformly fatal, progressive neurodegen-
erative disorders caused by the conversion of the cellular
prion protein, PrPC, to a misfolded conformation known
as the prion, or PrPSc, in which Sc stands for scrapie, the
prion disease of sheep and goats.1 In humans, prion dis-
eases have an incidence of approximately 1 death per 1
million individuals per year,2 and usually occur as simplex
cases in individuals with two wild-type (WT) copies of the
prion protein gene (PRNP [MIM 176640]), commonly
referred to as sporadic cases. A minority of cases are genetic
and, very rarely, prion disease can be environmentally
acquired.1 Creutzfeldt-Jakob disease (MIM 123400) caused
by the c.598G>A (dbSNP id rs28933385) mutation, which
encodes a p.Glu200Lys (E200K) substitution in PrP, is the
most common genetic form of prion disease worldwide.3
This point mutation was first identified in 19894 and was
established as a dominant Mendelian cause of disease by
1991.5–7 Disease penetrance inmutation heterozygotes ap-
pears to reach 80%–100% by age 80.8,9 Reported estimates
of the mean age of onset in individuals with this mutation
range from 537 to 63,10 and the mean survival after disease
onset is 7 months.11
Three reports12,13 (see also Web Resources) have claimed
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The Americanticipation, a phenomenon in which successive genera-
tions exhibit progressively earlier disease onset or more
severe presentation.14 These studies reported a 7 to 14
year younger age of onset or death among children in
affected parent-child pairs, suggesting implications for
genetic counseling.
The only genetic mechanisms known to cause anticipa-
tion are the germline expansion of unstable repeats in
disorders such as Huntington’s disease and type 1 myoto-
nic dystrophy,15,16 and telomere shortening in disorders
such as dyskeratosis congenita and breast cancer.17,18
Anticipation in a genetic prion disease might raise the
question of whether disease in children is accelerated by
exposure to infectious material during their parents’
illness, however, the only known routes of human-to-hu-
man prion transmission are cannibalism19 and iatrogenic
exposure.20,21
Because a variety of sources of ascertainment bias are
known to contribute to false statistical signals of anticipa-
tion,14,22–25 we set out to determine whether the anticipa-
tion reported for Glu200Lys genetic prion disease could be
a statistical artifact. An individual’s observed age of onset
cannot be greater than the age at interview or ascertain-
ment, and previous studies have modeled the effects of
this right truncation of age of onset22 and provided
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however, require either a consistent, known set of ascer-
tainment criteria23 or the use of only a subset of available
data.26 In rare diseases, data may be too sparse for subset-
ting, and may not represent a unified ascertainment effort,
but rather consist of a mix of data points ascertained retro-
spectively (through family histories of varying depth and
quality), directly (symptomatic individuals seen clinically),
and prospectively (asymptomatic individuals with a muta-
tion, followed for varying amounts of time). We therefore
sought to model ascertainment bias due to left- and right-
truncation not of the age of onset per se, but of the year of
onset. Because the Glu200Lys substitution was discovered
only 25 years ago and most prion surveillance programs
and clinical centers have been established even more
recently, we hypothesized that the selective ascertainment
of parents and children whose deaths both occurred
within this 25-year window could explain the reported dif-
ferences in parent and child age of death.
To test this hypothesis, here we combine data from
four national prion study centers to assemble the largest
Glu200Lys cohort (n ¼ 217 individuals) yet reported. We
first create a simulation of the ascertainment of parent-
child pairs with a mutation to identify conditions under
which naive paired t tests will detect a false signal of antic-
ipation. We explore methods for detecting and controlling
for this ascertainment bias. We then apply our analytical
framework to our Glu200Lys data set and successfully
reproduce the anticipation reported by other groups but
demonstrate that this anticipation is a false positive due
to ascertainment bias.Material and Methods
Data Collection
We combined data collected on Glu200Lys individuals and their
families from four research centers with data collection practices
as follows.
Australian National Creutzfeldt-Jakob Disease Registry
Details of Australian National Creutzfeldt-Jakob Disease Registry
(ANCJDR) surveillance mechanisms, as well as data collection
and analysis methods, have been reported previously.27,28 In brief,
prospective national surveillance of CJD has been undertaken
since 1993 with CJD a Notifiable Disease throughout Australia
since 2006. ANCJDR collects detailed medico-demographic infor-
mation on suspect cases, including family histories, and provides
diagnostic tests including PRNP genotyping. Year and age of death
are primary variables with information on age at onset of first
symptom collected if available. Informed, written consent was
obtained from participants or legal next of kin. Ethical approval
was obtained from the Office of Research Ethics and Integrity at
The University of Melbourne.
German CJD Surveillance Unit
Details of German CJD surveillance have been reported previ-
ously.29–31 In brief, the Surveillance Unit in Goettingen has
collected data on all suspected prion disease cases in Germany
since 1993. Diagnostic information is obtained from reporting
hospitals and where possible, confirmation by autopsy is sought.
The Surveillance Unit also accepts clinical referrals, provides diag-372 The American Journal of Human Genetics 95, 371–382, Octobernostic tests including PRNP genotyping, and, where possible, col-
lects family history. Age of onset is defined from first symptom of
a progressive neuropsychiatric disorder by interview with family
members. Informed, written consent was obtained from partici-
pants or legal next of kin. Ethical approval was obtained from
the Ethical Committee at the University Medical School, Georg-
August University Goettingen.
MRC Prion Unit/NHS National Prion Clinic
The UK has had a centralized tertiary clinical referral service for
CJD since 1991. Since 2004, all suspected CJD cases from the UK
are referred to the NHS National Prion Clinic at the National Hos-
pital for Neurology and Neurosurgery (NHNN) at University Col-
lege London Hospitals NHS Trust. Age of onset was defined from
first symptom of a progressive neuropsychiatric disorder and fam-
ily history was obtained by interview with family members. Other
details of data collection have been described previously.32
Informed, written consent was obtained from participants or legal
next of kin. Ethical approval was obtained from the NHNN/Insti-
tute of Neurology Joint Research Ethics Committee.
Memory and Aging Center, University of California San Francisco
The UCSF cohort comprises symptomatic and asymptomatic indi-
viduals fromGlu200Lys families referred from the U.S. and abroad
to the rapidly progressive dementia and Prion Disease research
program since August 2001.33–35 PRNP genotyping36 was per-
formed at the National Prion Disease Pathology Surveillance
Center (Cleveland, OH), or by outside laboratories in some of
the individuals who were tested prior to UCSF referral or
lived abroad. Symptom onset was determined as previously re-
ported.37 A detailed, usually three generation, family pedigree
was made by a neurologist and/or clinical genetic counselor for in-
dividuals participating in research. Further data were collected
from medical records sent by referring physicians and/or from
direct contact with family members (by email or telephone).
Informed, written consent was obtained from research partici-
pants or legal next of kin. The UCSF data included in this study
have been collected through UCSF Institutional Review Board-
approved research protocols.
Data Annotation
Directly observed individuals were defined as those either seen
clinically at one of the four centers or officially reported to one
of the centers in its prion disease surveillance role. Indirectly
observed individuals were those ascertained through interview
with family members. Individuals were considered to have the
c.598>A mutation if they (1) had either a genotyping test indi-
cating the presence of the mutation or were related to someone
with a positive test and (2) had a diagnosis of CJD or (3) were
deemed to have died of CJD based on information obtained
from interviewed family members. Individuals were considered
to not have the mutation if they (1) had a genotyping test indi-
cating the absence of the c.598G>A mutation or (2) were related
to the family only by marriage and thus lacked a blood relation-
ship to any affected individual. The Glu200Lys substitution causes
CJD with nearly 100% penetrance,8,9 but individuals with twoWT
PRNP alleles have a very low disease incidence of only about 1 in 1
million per year.2 This incidence translates into a lifetime risk
roughly on the order of 1 in 10,000 for a WT individual. By Bayes’
rule, the high penetrance of themutation and rarity of nongenetic
CJD cases mean that any CJD case in a Glu200Lys pedigree is over-
whelmingly likely to be genetic. Therefore, we assumed that all
CJD cases in these pedigrees were due to the c.598G>A mutation.
Data on four individuals with CJD were flagged as questionable2, 2014



















of onset slope a
Slope
significant b
1 1989–2013 None 16.4 100% 93% 100% 0.67 100%
2 1950–2013 None 4.9 98% 19% 16% 0.22 100%
3 1880–2013 None 1.6 23% 3% 5% 0.06 100%
4 1989–2013 Declining 5%/year 10.7 100% 59% 83% 0.55 100%
5 1950–2013 Declining 5%/year 3.4 79% 14% 11% 0.18 100%
6 1880–2013 Declining 5%/year 1.4 18% 3% 6% 0.05 98%
7 1989–2013 Declining 1%/year 2.0 33% 6% 5% 0.26 100%
8 1950–2013 Declining 1%/year 0.9 12% 4% 5% 0.12 100%
9 1880–2013 Declining 1%/year 0.4 6% 1% 4% 0.04 85%
10 1989–2013 Exhaustive 0.2 5% 1% 5% 0.20 99%
Ascertaining only those individuals with disease onset within a historical window creates false signals of anticipation and heritability (Simulation 1). These false
signals are reduced, but not eliminated, by expanding the ascertainment window (Simulations 2 and 3). Probabilistic retrospective ascertainment (see text)
reduces these signals further (Simulations 4–9). Only when retrospective ascertainment is 100% exhaustive does anticipation become reliably nonsignificant
(Simulation 10).
aAverages from 1,000 simulations.
bPercentage of 1,000 simulations in which this figure was statistically significant at p < 0.05.due to uncertain diagnosis, uncertain relatedness to other individ-
uals or uncertain age at death; none of the results reported here
differed when the analysis was re-run excluding these individuals.
Missing PRNP codon 129 information was imputed from affected
family members when possible. For the purpose of assessing rates
of predictive genetic testing, ‘‘at-risk’’ individuals were defined
as those who were not symptomatic at last follow-up but who
did have a parent deemed to have the mutation, per the above
criteria. Recursively, individuals were also considered at-risk if
they had a parent who qualified as at-risk according to the above
definition.
Simulation
We hypothesized (see Introduction) that the selective ascertain-
ment of individuals with disease onset within a specified window
(for instance, 1989–2013) might explain reported anticipation in
Glu200Lys prion disease. To assess whether such an ‘‘ascertain-
ment window’’ was sufficient to create a false signal of anticipa-
tion, we created a simulation model in which parent and child
ages of onset are drawn from the same specified distribution but
ascertainment of parent-child pairs is selective based on year of
onset. For each round of simulation, we generated n ¼ 100,000
parent-child pairs. We only simulated parents and children with
the causative mutation. We wished to model a situation in which
individuals have been falling ill of prion disease continuously
throughout history, and will continue to do so into the future,
whereas our data are limited only by an artificial ascertainment
window. We therefore generated parents with a year of birth uni-
formly distributed from 1700 to 2000, in order to ensure that (1)
the density of disease onsets over our largest ascertainment win-
dow (1880 to 2013) would be uniform and that (2) observed years
of onset would effectively be left-truncated only according to our
ascertainment criteria and not according to the underlying simu-
lated distribution. We set the child’s birth to occur 28 5 6 years
after the parent’s birth, per the actual distribution from our data.
To simulate an age of onset distribution while accounting forThe Americcensoring due to deaths due to other causes (‘‘competing risks’’),
we first created a normally distributed 64 5 10 year age of onset
to approximate the distribution in our real data (see Results) and
then randomly censored individuals according to the U.S actuarial
life table for 2009 (see Web Resources). We did not model changes
in the life expectancy over the time periods considered here.
Further details of the specific simulations are explained in Results
and in the legends of Tables 1 and 2.
Statistical Analyses
All simulations and analyses of Glu200Lys pedigree data
were conducted in R 3.0.2. In order to demonstrate the effects
of ascertainment bias on the evidence for anticipation reported
by previous studies of genetic prion disease, we adopted methods
from those studies when possible. For paired t tests, all possible
parent-child pairs were generated from Glu200Lys pedigree struc-
tures using a SQL join operation. This results in multiple-counting
parents of multiple affected children and counting both as par-
ents and as children those individuals in the middle of pedigrees
with three or more affected generations. Multiple counting
means that pairs are not independent; this mirrors the methods
from at least one prior study of prion disease anticipation.13
Based on these paired lists of parents and children, differences
in parent and child age of onset were assessed using two-tailed
paired t tests (the R t.test function) for naive comparisons of
observed age of onset distributions. Correlation between parent
and child age of onset was assessed using linear regression (the
R lm function). Survival analysis utilized the R survival package.
For survival analysis, to avoid multiple-counting and ensure
independence of all pairs, we randomly selected one parent-child
pair from each pedigree and compared the survival curve for all
parents to that of all children using a log rank test (the R survdiff
function). Because we randomized which pairs were included, we
repeated this analysis for over 1,000 iterations and have reported
aggregate statistics. Source code and output are available online
(see Web Resources).an Journal of Human Genetics 95, 371–382, October 2, 2014 373
Table 2. Stratification of Simulated Data
Cohort Name Inclusion Criteria Anticipation p
Child early birth year Child born < 1939 16 years 0.009
Child late birth year Child born R 1939 18 years <0.0001
Child early death year Child year of onset
< 2000
26 years 0.0004
Child late death year Child year of onset
R 2000
15 years <0.0001
Child early death age Child age onset < 61 21 years <0.0001
Child late death age Child age onset R 61 11 years 0.003
Parent early death age Parent age onset < 70 12 years 0.01
Parent late death age Parent age onset R 70 20 years <0.0001
In n¼ 26 simulated parent-child pairs with independent and identically distrib-
uted ages of onset but ascertaining only those pairs whose onsets both fall
within 1989–2013, all subsets of data stratified according to the variables
defined in Table 3 of Pocchiari et al.13 still show significant anticipation.Results
Simulated Effects of Ascertainment Window
We generated 100,000 parent-child pairs with all individ-
uals harboring a dominant genetic mutation and ages of
onset for all individuals independent and identicallydistrib-
uted, corresponding to a scenario in which no anticipation
or heritability of age of onset are present (see Material and
Methods and Figure 1A). Themean age of onset without ac-
counting for censoring was 62, whereas the median age of
onset in survival analysis accounting for censoring due to
intercurrent deathswas 64.When considering all simulated
individuals, therewasnodifference inageofonset (p¼0.91,
two-tailed paired t test), no correlation between parent and
child age of onset (p¼ 0.53, linear regression), andno corre-
lation between the year of birth and age of onset for all indi-
viduals (p ¼ 0.59, linear regression).
Next we considered the effects of selectively ascertaining
individuals whose disease onset occurs within an ‘‘ascer-
tainment window,’’ which we define as a range of years
in which disease onsets can be observed. It is impossible
to ascertain ages of onset after 2013, the last year in which
our data were collected. Right-truncating the year of onset
at 2013 and considering all affected pairs introduced only
a very small difference between parent and child age of
onset (0.37 years, p < 0.0001, two-tailed paired t test).
Because we had generated parent-child pairs with years
of birth as early as 1700, only a minority of pairs was
affected by this right truncation. Spreading the simulated
pairs out over an even greater range of years of parent birth
(year 0–2000) made this anticipation cease to be significant
(p ¼ 0.31, two-tailed paired t test), indicating that right
truncation of year of onset is not sufficient cause a false
signal of anticipation. In practice, any real data set will
be both left-truncated (when researchers began to study
the disease) and right-truncated (at the present year
or when the study stopped, whichever is earlier). For374 The American Journal of Human Genetics 95, 371–382, OctoberGlu200Lys CJD, we reasoned that ascertainment rates
would be higher after the discovery of the disease’s causal
mutation in 1989,4 so we next considered the effects of
ascertaining only those individuals whose year of onset
occurs between 1989 and 2013 inclusive.
When only those simulated pairs in which parent and
child disease onset both occurred within this window
were considered (Figure 1A), we observed 17 years of antic-
ipation (p < 0.0001, two-tailed paired t test, Figure 1B).
Because parents were born, on average, 28 years earlier
than their children, yet the window of observation was
only 25 years long, the ascertained pairs were vastly en-
riched for those in which the child dies at least 3 years
younger than the parent. Under these conditions, we
also observed an artifactual correlation between year of
birth and age of onset, with slope of 0.67, (p < 0.0001,
linear regression, Figure 1C). This relationship is intuitive
because an individual born in 1970, for instance, can
only be included in the data set if onset occurs by age 43
(year 2013), and an individual born in 1940 can only be
included if onset occurs at age 49 or later (year 1989).
Year of birth/age of onset correlation is therefore a conse-
quence of ascertaining only individuals with the year of
onset within a particular window. This problem has previ-
ously been noted in Huntington’s disease pedigrees.38
Among the ascertained pairs, parent and child age of onset
were also correlated with a slope of 0.48 (p< 0.0001, linear
regression, Figure 1D). In single parent-offspring regres-
sion, the slope can be doubled to obtain an estimate of
phenotypic variance explained by additive genetic herita-
bility plus environmental effects.39 Applying this formula
to the ascertained data would suggest that age of onset
is up to 96% heritable. Because the true distributions of
parent and child ages of onset in our simulation were
neither different nor correlated, this shows that the year
of onset ‘‘windowing’’ simulated here is sufficient to create
false signals of both anticipation and heritability. We
confirmed this finding through 1,000 iterations with the
same set of simulation conditions and n ¼ 100 ascertained
pairs to simulate a realistic sample size for a rare disease
(Table 1, Simulation 1).
Because we knew the anticipation and heritability
identified in our above simulation to be false signals, we
asked whether improved ascertainment or simple analyt-
ical methods could disprove them. We considered a two-
step ascertainment model; in the first step, we ascertained
all individuals with disease onset between 1989 and 2013
(simulating clinical visits), and in the second step we ascer-
tained any and all individuals still alive and well as of 2013
who were parents or children of the individuals ascer-
tained in step 1 (simulating genetic testing and prospective
follow-up of individuals with the mutation). When we
compared parent and child survival curves under this
two-step ascertainment model in Kaplan-Meier survival
analysis, the median age of onset of children was greater
than that of parents (64 versus 62 years, p < 0.0001, log
rank test). This counter-intuitive finding of later child2, 2014
Figure 1. Simulation of Ascertainment
Bias Due to Year of Onset Windowing
(A) Visual representation of a subset of
simulated data. Parent-child pairs are ar-
ranged along the y axis. Parent is born on
orange square and has disease onset on or-
ange X; child is born on blue square and
has disease onset on blue X. Age of onset
distributions are identical, but in Simula-
tion 1, only those pairs in which both indi-
viduals have onset between 1989 and 2013
inclusive (red vertical lines) can be ascer-
tained. In the above example, only one
pair (#49) meets these criteria.
(B) Among ascertained pairs in Simula-
tion 1, children have almost categorically
younger onset than their parents, leading
to 17 years of observed anticipation (p <
0.0001, two-tailed paired t test). For visibil-
ity, a subset of simulated points is shown.
(C) Ascertainment windowing introduces
an artifactual correlation between year
of birth and age of onset, slope ¼ 0.67
(p < 0.0001, linear regression).
(D) Ascertainment windowing also leads
to a correlation between parent and child
age of onset and thus a false signal of heri-
tability (slope ¼ 0.48, p < 0.0001, linear
regression).
(E) Ascertained pairs are supplemented
with those pairs where one individual’s
onset occurs in 1989–2013 and the other
is alive and well as of 2013. The plot shows
that the median survival of parents and
children in Kaplan-Meier curves depends
upon what proportion of alive and well in-
dividuals are included. If 0% are included,
then 17 years anticipation are observed,
just as in (B). As ascertainment increases,
the anticipation is reduced. As inclusion
of alive and well individuals approaches
100%, children have longer survival than
parents. This is because more of the chil-
dren are censored, so their age of onset dis-
tribution better reflects the hypothetical
distribution of age of onset without the
influence of competing risks.onset can be explained as follows. Because parents are born
earlier than children, pairs in this two-step ascertainment
model are predominantly ones in which the parent dies
of genetic prion disease between 1989 and 2013 while
the child is alive and well in 2013. In such pairs, the par-
ent’s age of onset distribution is truncated by competing
risks (parents who would have had older disease onsets
were never ascertained because they died of other causes
first, thus making disease onset appear younger). The
child’s age of onset distribution, however, is less affected
by competing risks (children who would have older disease
onsets are ascertained through genetic testing even if they
will never develop the disease in their lifetimes).The American Journal of Human GRecall that in the two-step ascer-
tainment model above, an affected
individual is ascertained in step 1,and if that individual has a parent or child alive and well
in 2013, then that parent or child is always ascertained.
In practice, however, it is difficult to ascertain 100%
of asymptomatic relatives of an affected individual. We
therefore also modeled incomplete ascertainment of asymp-
tomatic individuals. When we did so, we saw that the false
signal of anticipation from naive t tests was not fully cor-
rected (Figure 1E). The difference in median survival ac-
cording to the log rank test was 17 years when no censored
individuals were included, and this difference shrunk to 7
years when 20% of individuals alive and well in 2013 were
included, and 2 years when 50% of such individuals were
included. This indicates that accounting for censoredenetics 95, 371–382, October 2, 2014 375
observations is not sufficient to remove false signals of
anticipation unless ascertainment of censored individuals
is exhaustive. In long-term studies of predictive genetic
testing for neurodegenerative diseases, it has been
reported that only 3% to 24% of individuals with risk of
having inherited a mutation pursue predictive genetic
testing.40–45 Survival analysis including asymptomatic in-
dividuals with a mutation is therefore unlikely to mitigate
false signals of anticipation and heritability in this disease
setting.
We also asked whether including year of birth as a
covariate could eliminate the false signal of heritability
we observed in our simulation. When both parent age of
onset and child year of birth were used in a linear model
to explain child age of onset, only the child’s year of birth
proved to be correlated (slope ¼ 0.72, p < 0.0001, linear
regression), whereas parent age of onset was no longer sig-
nificant (p ¼ 0.73, linear regression). When we simulated
an age of onset that truly was heritable, this method
reduced, but did not eliminate, the estimate of heritability
(see Table S1 available online).
Simulated Effects of Different Ascertainment Criteria
In Simulation 1 (Table 1) we assumed that it was only
possible to include individuals directly ascertained within
the window from 1989 to 2013. In reality, some Glu200Lys
families have been followed since as early as 19637 and it is
also possible to obtain information on deceased individ-
uals retrospectively through interview with family mem-
bers, though it can be more difficult for individuals whose
year of death is long past.46 We therefore asked whether
false anticipation and heritability would still be observed
with larger or more flexible ascertainment windows. In
this analysis, we limited the number of ascertained pairs
to 100 in order to simulate a realistic sample size for a
rare disease. Expanding the size of the direct ascertainment
window back to 1950 or 1880 (but still not adding indirect
ascertainment) decreased the strength of the false signals
quantitatively, but did not reliably eliminate them,
even when the window was longer than a human lifespan
(Table 1, Simulations 1–3).
Next, we considered including some indirectly ascer-
tained individuals. To simulate retrospective ascertain-
ment, we first directly ascertained individuals with onset
within the window, then ascertained any parents or chil-
dren thereof whose onset had already occurred prior to
the beginning of the window. We hypothesized that it
might be more difficult to ascertain individuals who died
long ago, so for indirectly ascertained individuals we
applied a linear reduction in ascertainment probability ac-
cording to how many years prior to the beginning of the
ascertainment window the individual had disease onset.
In Simulation 4 (Table 1), for instance, direct ascertain-
ment from 1989-2013 is exhaustive, but the probability
of indirect ascertainment declines by 5% for each year
prior to 1989 that an individual has onset so that, for
instance, an individual with onset in 1988 can be retro-376 The American Journal of Human Genetics 95, 371–382, Octoberspectively ascertained with 95% probability, in 1987
with 90% probability, and so on. Including some indi-
rectly ascertained individuals in this manner further
reduced the magnitude of anticipation but did not
completely eliminate it in most scenarios tested (Simula-
tions 4–9). The false signal of heritability was weaker
than that of anticipation and could be reliably reduced
to statistical insignificance in the most extreme scenarios
tested (Simulations 6–9). Only when indirect ascertain-
ment was 100% exhaustive and independent of the year
of onset (Simulation 10) did a signal of anticipation cease
to be detected, though a year of birth/age of onset correla-
tion still existed.
Together, our simulations demonstrate that ascertaining
individuals over a larger time window or including some
indirect ascertainment (retrospective phenotyping) can
quantitatively reduce the false signals of anticipation and
heritability but that these false signals are still likely to be
observed as statistically significant under anything other
than almost complete ascertainment. Our results indicate
that whenever retrospective ascertainment is less than
exhaustive, there is a risk of observing false signals of antic-
ipation and heritability of age of onset.
Stratification of Simulated Data
One recent report of anticipation in Glu200Lys genetic
prion disease13 argued that the observed anticipation
must be real because anticipation was observed, using
paired t tests, within every subset of 26 parent-child pairs
when these were stratified by age of death, year of birth,
or year of death. To determine whether such an analysis
could indeed rule out a false positive due to ascertainment
bias, we stratified 26 simulated parent-child pairs with
onset between 1989 and 2013 in the same way described
in the previous report (Table 2). In our simulation, antici-
pation is not real, yet a strong signal of anticipation is
nevertheless observed in all eight strata. Therefore, these
methods of stratification do not eliminate spurious signals
of anticipation due to ascertainment bias.
Characteristics of Glu200Lys Pedigree Data
We combined data on Glu200Lys families from four inde-
pendent study centers worldwide (Table 3). Each individ-
ual data set reflected a different method of ascertainment
(see Material and Methods) and accordingly, the propor-
tion of individuals ascertained indirectly or asymptomatic
as of last follow-up varied considerably (Table 3).
Of individuals whose disease onset or death was directly
observed by one of the study centers, 65% had no reported
family history of prion disease. This figure might reflect
some combination of (1) incomplete reporting of family
history, (2) underdiagnosis of affected individuals in earlier
generations, (3) censoring of asymptomatic individuals
with the mutation upon death due to other causes, and
(4) de novo mutations. Similarly, we knew the genotypes
of only 22% of at-risk individuals (see Material and
Methods) in our data sets. Together, these figures suggest2, 2014














ANCJDR 1993 24 7 42% 8%
German CJD Surveillance 1993 32 3 38% 3%
MRC Prion Unit 1991 57 29 25% 23%
UCSF 2001 104 58 73% 37%
All 217 97 52% 25%
Data from the four study centers varied in terms of the length of time for which data had been collected, the degree of indirect ascertainment, and the ascertain-
ment of asymptomatic individuals with the mutation. See Material and Methods for details.that neither retrospective ascertainment nor prospective
following of individuals with the mutation are exhaustive
in our data set.
Disease Duration and Genotypic Influence
Disease duration was defined as time from first symptom
(see Data Collection in Material and Methods) to death.
Disease duration followed a nonnormal distribution (p <
0.0001, Shapiro-Wilk normality test) with a median of
162 days (n ¼ 61, interquartile range 205 days), similar
to the figure reported elsewhere.11 Disease duration did
not differ by study center (p ¼ 0.35, Kruskal-Wallis test,
n¼ 61) or between directly and indirectly ascertained indi-
viduals (p¼ 0.08, Kruskal-Wallis test, n¼ 38 and 23 respec-
tively). PRNP codon 129 information was available for a
subset of individuals with known disease duration. Among
individuals with a haplotype encoding Glu200Lys cis
129Met, disease duration was shorter for individuals
with a trans allele encoding 129Met (median of 137 days,
n ¼ 25) than a trans allele encoding 129Val (median of
426 days, n ¼ 7) and this difference was significant (p ¼
0.02, Kolmogorov-Smirnov test), consistent with previ-
ously reported data.11 Disease duration appeared to differ
between haplotypes encoding Glu200Lys cis 129Met
(n ¼ 42) and Glu200Lys cis 129Val (n ¼ 6) proteins, with
a median duration of 137 versus 331 days respectively
(p ¼ 0.04, Kolmogorov-Smirnov test), although trans
codon 129 information was not available for all of these in-
dividuals, so it is possible that the longer duration among
cis 129Val individuals might be due to higher rates of
codon 129 heterozygosity. Because disease duration was
generally a year or less and our data included age of onset
for some individuals but age of death for others, we
decided to consider age of onset and death interchange-
ably in the anticipation analysis, preferring age of death
when both were available.
Age of Onset or Death and Genotypic Influence
Overall, the mean age of onset or death in affected individ-
uals was 62 5 10 years (5SD, n ¼ 158) and was approxi-
mately normally distributed (p ¼ 0.36, Shapiro-Wilk
normality test; Figure 2A). The median observed age of
onset or death was 63 years (n ¼ 158). The median roseThe Americto 64 years when we included asymptomatic individuals
with the mutation, censored at date of last follow-up or
death due to other causes, and applied a survival analysis
(n ¼ 207). This survival analysis indicated 93% disease
penetrance by age 80, within the range of previously re-
ported estimates,8,9 but we note that this figure is biased
upward by the ascertainment of affected families and
incomplete genotyping of unaffected individuals. To our
knowledge, 64 years is older than any other measure
of central tendency of age of onset for this mutation yet
reported, probably because our use of survival analysis ac-
counts for censoring due to competing risks, whereas other
published estimates have been based simply on observed
ages of onset.3,7,10,47 Even our estimate is likely biased
downward due to incomplete genotyping of unaffected
individuals.
Age of onset or death did not differ by study center (p ¼
0.18, Model I ANOVA, n ¼ 158), sex (p ¼ 0.74, unpaired
t test, n ¼ 132), or mode of ascertainment (direct versus in-
direct, p ¼ 0.66, unpaired t test, n ¼ 158). Among individ-
uals with a haplotype encoding Glu200Lys cis 129Met, age
of onset or death did not differ between trans 129Met (n ¼
46) and trans 129Val (n ¼ 10) genotypes (p ¼ 0.71, two-
tailed unpaired t test; p ¼ 0.39, log rank test, n ¼ 64 Met-
Met versus 17 Met-Val including censored individuals),
consistent with a previous report.48 It was unclear whether
age of onset or death might differ between individuals
with haplotypes encoding Glu200Lys cis 129Met versus
Glu200Lys cis 129Val, because only a weak trend could
be detected whether censored individuals were included
(censored median 64 versus 57 years, p ¼ 0.05, log rank
test, n ¼ 142 Met versus 13 Val) or excluded (mean 63
versus 56 years, p ¼ 0.11, two-tailed unpaired t test, n ¼
105 Met versus 10 Val). Because trans codon 129 did not
influence age of onset or death and because a child’s
cis codon 129 is inherited from the affected parent, we
deemed it unnecessary to consider codon 129 genotype
in our anticipation analyses.
Ascertainment Bias in Glu200Lys Pedigree Data
Excluding asymptomatic individuals, the year of disease
onset or death was known for 94% of directly ascertained
individuals (68 of 72) and 55% of indirectly ascertainedan Journal of Human Genetics 95, 371–382, October 2, 2014 377
Figure 2. Ascertainment Bias and Antici-
pation in Glu200Lys Pedigree Data
(A) Distribution of age of onset or death by
ascertainment mode.
(B) Years of onset or death, when known,
occur overwhelmingly in the 25-year
window since the mutation’s discovery in
1989.
(C) Year of birth and age of onset are
artifactually correlated. This correlation
is strongest in directly ascertained indi-
viduals (black line) but remains highly
significant when indirectly ascertained
individuals (gray points) are included in
addition (dashed black line).
(D) Parent versus child age of onset or
death. Points below the diagonal line indi-
cate pairs in which the child dies younger
than the parent. Directly ascertained pairs
(black points) fall categorically below the
line, pairs with one directly ascertained
member are largely below the line (gray
points), and pairs in which both individ-
uals are indirectly ascertained fall on both
sides (white points).individuals (50 of 91). Year of disease onset or death
occurred between 1989 and 2013 in 92% of all individuals
for whom this variable was known (Figure 2B). This 25-year
window was shorter than the typical difference between
parent and child year of birth, which was 28 5 6 years
(mean 5 SD, n ¼ 150 including unaffected individuals),
thus partially limiting ascertainment to parent-child pairs
in which the child died at least 3 years younger than the
parent. For individuals ascertained directly, year of birth
and age of onset were even more strongly correlated than
in our simulation (slope¼0.79, p< 0.0001, linear regres-
sion, Figure 2C, black line). The correlation weakened
only slightly when indirectly ascertained individuals
were included as well (slope ¼ 0.48, p < 0.0001, linear
regression, Figure 2C, dashed line).
Our simulation (see above) indicated that ascertain-
ment bias could introduce false signals of heritability.
We did not, however, observe any correlation between
parent and child age of onset (p ¼ 0.99, linear regression,
n ¼ 39 pairs) nor in sibling pair ages of onset (p ¼ 0.63,
linear regression, n ¼ 26 pairs). Thus we do not find any
signal, whether real or artifactual, that age of onset in
this disease is heritable. This is not surprising because
our simulation indicated that false signals of heritability
are weaker than false signals of anticipation (Table 1),
and the small size of our data set might also leave us un-
derpowered to detect any true heritability of age of onset
that might exist.378 The American Journal of Human Genetics 95, 371–382, October 2, 2014Strength of Anticipation Signal
Depends upon Degree of
Ascertainment Bias
Because signatures of ascertainment
bias were strongly evident in our
data, we expected to see a differencebetween parent and child age of onset in observed pairs.
On the basis of our simulation results (Table 1), we hypoth-
esized that the strength of the anticipation signal from
naive paired t tests would vary depending on how flexible
we were able to make our ascertainment window, within
the constraints of our available data. When we considered
only pairs in which both parent and child were ascertained
directly, we observed 28 years of anticipation (p ¼ 0.002,
two-sided paired t test, n ¼ 4 pairs). When we additionally
included pairs with one indirectly ascertained individual,
this figure dropped to 15 years (p ¼ 0.0002, two-sided
paired t test, n ¼ 20 pairs). When we also included pairs
in which both individuals were ascertained indirectly,
this dropped further to 7 years (p¼ 0.005, two-sided paired
t test, n ¼ 39 pairs). Thus, the number of years of anticipa-
tion observed depends upon how narrow the ascertain-
ment window is and the mechanism of case reporting.
The strength of the anticipation signal also differed by
study center according to the extent of ascertainment
bias in each individual data set. The UCSF data set, which
was the largest and had both the highest percentage of
indirectly ascertained individuals (73%) and the least cor-
relation between year of birth and age of onset or death
(slope ¼ 0.41), showed the least evidence of anticipation
(1 year, p ¼ 0.68, two-sided paired t test). The MRC Prion
Unit showed a marginal paired difference (7 years,
p ¼ 0.10, two-sided paired t test), whereas the Australian
and German cohorts showed larger differences (18 years,
p ¼ 0.05 and 31 years, p ¼ 0.03 respectively, two-sided
paired t test).
Application of Survival Analysis to Glu200Lys
Anticipation
The foregoing analysis indicated that our data exhibited a
nominal signal of anticipation when analyzed with naive
paired t tests. Because this signal depended upon the de-
gree of ascertainment bias, and because our data exhibited
signatures of ascertainment bias similar to what we had
observed in our simulation, we suspected that the anticipa-
tion we observed was an artifact. We next set out to deter-
mine whether a survival analysis including asymptomatic
individuals with the c.598G>A mutation would correct
this artifact. Based on our simulation results (Figure 1E)
and the fact that our ascertainment of asymptomatic
individuals with the mutation was not exhaustive, we ex-
pected that survival analysis would not fully eliminate
the signal of anticipation in our Glu200Lys data. For the
survival analysis, we considered all parent-child pairs in
which both individuals harbored the mutation, regardless
of censored status. To ensure independence of tested pairs
and avoid multiple counting, we randomly selected one
such pair from each pedigree and compared parent and
child survival curves. Across 1,000 iterations, parent and
child survival curve medians differed by an average of 7
years (log rank test p < 0.05 in 82% of iterations). Because
our simulation indicated that more thorough ascertain-
ment of censored individuals reduces artifactual anticipa-
tion signals (Figure 1E), we repeated the same analysis on
only the UCSF and MRC Prion Unit cohorts, which had
the highest proportion of asymptomatic individuals with
the mutation (Table 3). Within these cohorts, the median
difference in parent and child survival curves was only 1
year and was usually not significant (p < 0.05 in only 8%
of 1,000 iterations). This is consistent with the hypothesis
that observed parent-child age of onset differences in
Glu200Lys prion disease are due to incomplete ascertain-
ment and not due to true anticipation.
Anticipation in Age at Death Due to Other, Non-Prion,
Causes
The foregoing analyses suggested that the anticipation we
observed in Glu200Lys families could be attributed entirely
to ascertainment bias. We reasoned that if this were true,
then anticipation in age of death might be observed in
deaths attributable to other causes as well, with these unre-
lated deaths providing a kind of negative control. When
we compared age at death for all parent-child pairs in our
data set in which neither individual had CJD listed as cause
of death, we observed 14 years of anticipation (p ¼ 0.002,
two-sided paired t test, n ¼ 37 pairs). In many cases, the
cause of death was not listed or was ambiguous, so we
could not rule out the possibility that some of those indi-
viduals might actually have died of undiagnosed or unre-
ported prion disease. When we therefore considered only
those pairs in which each individual was known not toThe Americharbor the mutation (see Material and Methods) and/or
died of a known cause clearly distinct from prion disease
(cancer, heart attack, accident, etc.), the anticipation
grew to 35 years (p ¼ 0.001, two-sided paired t test, n ¼ 9
pairs). This set included some individuals who had died
much younger than the typical age of onset for Glu200Lys
prion disease (Figure 2A), introducing a potential new
source of ascertainment bias as individuals who die
young might be counted as children but are unlikely
to ever become parents.14 When we further filtered our
data to include only individuals with age at death greater
than 40, 16 years of anticipation were still observed
(p ¼ 0.002, two-sided paired t test, n ¼ 5 pairs).Discussion
The prediction of age of onset in those carrying mutations
causal of neurodegenerative diseases is important for ge-
netic counseling, clinical trial design,49,50 and understand-
ing of fundamental disease mechanisms. We chose to
investigate bias in a specific genetic prion disease as it
has been reported12,13 that Glu200Lys genetic prion dis-
ease exhibits anticipation, with children succumbing to
disease 7 to 14 years younger than their parents on
average. We approached this claim with skepticism; the
causal mutation is not a repeat expansion and human
prion strains are not transmitted in childbirth or through
casual contact between people,51–53 leaving no obvious
mechanism for anticipation. Such a large decrease in age
of onset in germline transmission ought to lead to juvenile
onset cases within a few generations, as observed in repeat
expansion disorders,15 yet no such cases are observed in
Glu200Lys families (Figure 2A). In the present study, we
considered the possibility that reported evidence of antic-
ipation in Glu200Lys prion disease arises instead from
ascertainment bias.
We tested for anticipation in our data using naive paired
t tests, and we did observe a statistically significant dif-
ference between parent and child age of onset, but four
separate lines of evidence argue that this difference is arti-
factual rather than biological. First, 92% of known years of
onset or death for CJD-affected individuals in our data set
fell within the 25-year window from the mutation’s dis-
covery in 1989 to the time of our study in 2013, whereas
parents were born on average 28 years earlier than their
children. This enriches for pairs in which children die at
least 3 years younger than their affected parent. Pairs in
which children die older than their parents are much less
likely to be observed during this time window. Second,
we observed an artifactual correlation between year of
birth and age of onset reflective of this ‘‘windowing’’ effect
because individuals born later in time are only captured in
this data set if they have earlier onset. The distribution of
ages of onset is therefore shifted older for a parent’s year
of birth (for instance, 1920) than for their child’s year
of birth (for instance, 1950). Third, the strength of thean Journal of Human Genetics 95, 371–382, October 2, 2014 379
anticipation signal we observed depended upon how
strictly the data were limited by the ascertainment win-
dow. When we required that both parent and child had
to be directly observed as patients by the study centers
contributing data, we observed 28 years of anticipation.
When all indirectly ascertained individuals were also
included, this figure dropped to 7 years, and when we per-
formed survival analysis on only the data from two centers
most active in performing predictive genetic testing, we
saw no difference in age of onset at all. Fourth, when using
naive paired t tests, we observed anticipation even among
individuals in our pedigrees who did not harbor the muta-
tion and/or died of causes unrelated to prion disease.
None of the three previous studies reporting Glu200Lys
anticipation12,13 (see also Web Resources) presented data
on the distribution of year of onset, tested for correlation
between year of birth and age of onset, or carried out a
negative control by assessing anticipation in unrelated
deaths as we have done here. One of these studies12 found
a stronger anticipation (14 years rather than 7) when only
directly genotyped individuals were included, similar
to our finding that the strength of anticipation depends
upon the duration of the ascertainment window. We
showed that the stratification analyses, as performed in
one study,13 do not remove the effects of ascertainment
bias. Because anticipation was observed in certain analyses
of our data as well, we consider it likely that the differ-
ences between our study and the previous studies arise
from differences in methodology rather than differences
in whether anticipation is truly present in the study
population.
In assessing the evidence for anticipation in Glu200Lys
prion disease, we have created a simulation model with
relevance to other diseases as well. In contrast to previous
studies of anticipation, we consider ascertainment to be
limited by year of onset, not by age of onset per se. In gen-
eral we find that ascertaining only those individuals with
onset within a restricted time period is sufficient to create
robust false signals of anticipation. This is of general
concern because the genetic causes of many dominant
Mendelian disorders were identified within the past
25 years, leaving a relatively narrow window for ascertain-
ment. Our simulation shows that even high rates of retro-
spective ascertainment are unlikely to completely remove
the resulting false signal of anticipation. Although certain
statistical methods can help to correct for this bias when
ascertainment criteria are consistent or data sets large
enough to allow subsetting, we believe our own data may
be typical of some rare diseases in representing a mixture
of ascertainment modes, with both retrospective and
prospective phenotyping present but nonexhaustive. For
such data sets, we agree with the view54 that statistical tests
alone might be inadequate to discriminate between situa-
tions with and without anticipation. We believe that one
route toward preventing spurious claims of anticipation
such as seen in Glu200Lys genetic prion disease might lie
not in the requirement of more rigorous statistical tests380 The American Journal of Human Genetics 95, 371–382, Octoberbut in an expectation of thorough and transparent assess-
ment of a data set’s degree of bias. Toward that end, we pro-
pose that future studies’ reporting factors that determine
age of onset in adult-onset dominant conditions should
be expected to provide (1) a histogram of year of onset or
death, (2) a test for correlation between year of birth and
age of onset, (3) descriptive statistics on the extent of retro-
spective ascertainment and predictive genetic testing or
prospective follow-up, and (4) a test for anticipation in
deaths of other causes. Our results also have implications
for study design in adult-onset genetic diseases; year
of birth information should be collected, asymptomatic
individuals with a mutation should be tracked, and retro-
spective ascertainment should be as thorough as possible.
These measures will make it easier to quantify and reduce
ascertainment bias.
Though heritability of age of onset was not observed
in our Glu200Lys data, we noticed in our simulation that
windowed ascertainment can also create a false signal
that age of onset is heritable. This false signal could easily
be disproven by including child year of birth as a covariate
in parent-offspring regression. Our result suggests that esti-
mates of the heritability of age of onset in genetic disease
made based on parent-offspring regression ought to be
scrutinized carefully and accepted only if the parent-child
age of onset correlation remains after controlling for year
of birth.
In summary, the phenomenon of anticipation previ-
ously reported in Glu200Lys prion disease is likely an arti-
fact. Ascertainment bias is a pervasive problem in age of
onset in genetic disease but can be reduced through
appropriate data collection methods and recognized with
simple analytical tools.Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/ajhg.Acknowledgments
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